Pediatric Exclusivity Would Be Reduced To Three Months Under Bipartisan Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
The Lower PRICED Drugs Act from Sens. Lott (R-Miss.) and Stabenow (D-Mich.) also proposes to expand generic competition to non-“Orange Book”-listed antibiotics and to revise how 30-month stays are applied.
You may also be interested in...
Rep. Waxman Becomes Key Legislator On Biopharma Issues With House Flip
The congressman will likely support follow-on biologics legislation and other reforms sought by the generic industry as chairman of Government Reform Committee and as a senior member of Energy & Commerce Committee.
Rep. Waxman Becomes Key Legislator On Biopharma Issues With House Flip
The congressman will likely support follow-on biologics legislation and other reforms sought by the generic industry as chairman of Government Reform Committee and as a senior member of Energy & Commerce Committee.
Generic Drug Review Backlog Criticized At Appropriations Hearing
Sen. Kohl (D-Wisc.) requests a report on FDA’s efforts to improve its generic approval process.